| Qualification Type: | PhD |
|---|---|
| Location: | London |
| Funding for: | UK Students, EU Students |
| Funding amount: | Stipend at UKRI rate |
| Hours: | Full Time |
| Placed On: | 26th November 2025 |
|---|---|
| Closes: | 12th January 2026 |
| Reference: | CDT-AMR 2026 002 |
Supervisors:
Abstract
This project explores a novel therapeutic strategy for Acinetobacter baumannii, a top-priority AMR pathogen, by investigating the synergistic effects of monoclonal antibodies and colistin. Building on extensive preliminary data, the project aims to uncover the mechanisms behind this synergy using advanced biophysical and molecular techniques. The findings will lay the groundwork for clinical application and contribute to the development of targeted therapies for resistant bacterial infections.
Approach and Methods
Impact and Outlook
This project will
Training and Student Development
The successful applicant will gain expertise in:
Research Environment
Hoogenboom Lab: Pioneers in AFM imaging of bacteria, supported by BBSRC and Wellcome.
Brown Lab: Leader in pneumonia pathogenesis, equipped for microbiology and screening assays, MRC and Wellcome-funded.
Both labs promote an open, collaborative culture and have a strong track record of PhD supervision.
Desirable Prior Experience
Some prior experience in basic microbiology, immunology, and/or microscopy would be an advantage, but not essential.
How to apply
This project is offered as part of the Centre for Doctoral Training in Engineering Solutions for Antimicrobial Resistance. Further details about the CDT and programme can be found at AMR CDT webiste
Applications should be submitted by 12th January 2026.
Type / Role:
Subject Area(s):
Location(s):